Intravac, a company specializing in R&D for viral and bacterial vaccines will partner with CDMO Celonic for the development and manufacture of a COVID-19 vaccine. The vaccine will be based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc's proprietary Outer Membrane Vesicle (OMV) technology. This joint vaccine venture is expected to produce a result for clinical testing in 2021. In addition to offering global clinical trial logistics services, Yourway offers a personalized approach to care through our direct-to-patient service offering. Direct-to-patient delivery is often the most effective approach to continuing trials, especially during times as volatile as these.